Augusto Villanueva Rodriguez, MD
Hepatology · New York, NYNPI 1447888318
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $30,850 of the $33,192 with a category attached, or 92.9%. 14 manufacturers reported payments, led by AstraZeneca at 25.9% of the total. Reporting peaked in 2022 at $14,886 and has fallen 91.4% since, to $1,280 in 2025.
Across 36 payments — averaging $921.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$9K
- Genentech, Inc.$8K
- E.r. Squibb & Sons, L.L.C.$8K
- Bristol Myers Squibb$3K
- Fujifilm Healthcare Americas Corporation$2K
- Genentech USA, Inc.$2K
- plus $2K from 8 others
What the payments were for
- Consulting fees$30,85093%
- Speaking & faculty fees$5002%
- Travel & lodging$450%
- Food & beverage$1,7975%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 3 | $8,604 |
| Genentech, Inc. | 9 | $8,372 |
| E.r. Squibb & Sons, L.L.C. | 3 | $8,370 |
| Bristol Myers Squibb | 2 | $2,700 |
| Fujifilm Healthcare Americas Corporation | 3 | $1,994 |
| Genentech USA, Inc. | 1 | $1,555 |
| Gilead | 6 | $506 |
| Agilent Technologies, Inc. | 1 | $500 |
| Intercept Pharmaceuticals, Inc. | 1 | $236 |
| Shockwave Medical, Inc | 1 | $188 |
| AbbVie | 3 | $59 |
| Calliditas Therapeutics US Inc. | 1 | $55 |
| Ipsen Biopharmaceuticals, Inc | 1 | $33 |
| Madrigal Pharmaceuticals | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IMFINZI$8,563
- OPDIVO$7,470
- TECENTRIQ$4,200
- uTASWako AFP-L3$1,994
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$188
How this compares
$33,192 in reported general payments places this provider in the 65th percentile of 29 hepatology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EpclusaSofosbuvir/Velpatasvir | 15 | $342,759 |
| XifaxanRifaximin | 35 | $108,107 |
| Ursodiol | 73 | $6,741 |
| Lactulose | 32 | $757 |
| Carvedilol | 85 | $526 |
| Azathioprine | 20 | $479 |
| Mycophenolate Mofetil | 13 | $362 |
| Spironolactone | 17 | $151 |
| Omeprazole | 15 | $89 |
| Furosemide | 12 | $23 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadEpclusa | $506 | $342,75915 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 29 hepatology providers in New York.
Other hepatology in New York
- Robert BrownNew York$967K
- Douglas DieterichNew York$830K
- Arun JesudianNew York$828K
- Albert MinNew York$277K
- Meena BansalNew York$208K
- Tatyana KushnerNew York$181K
- Howard WormanNew York$119K
- Jawad AhmadNew York$30K
- Joseph OdinNew York$18K
- Jennifer LeongNew York$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.